Entera Bio develops oral tablet versions of injectable peptide and protein medicines, starting with an osteoporosis candidate. ENTX reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | Guggenheim | Initiated | Buy | |
| Sep 18 | Leerink Partners | Initiated | Buy |
Seasonality
How ENTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in ENTX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENTX is in one of them and how their past ENTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ENTX in an article yet. Here's the latest on the wider market.
About Entera Bio
Entera Bio is a clinical stage company developing oral tablet versions of peptide and protein medicines that are usually given by injection. Its most advanced product candidate, EB613, is an oral form of teriparatide being studied as a treatment for osteoporosis, a condition that weakens bones and raises fracture risk. The company's N-Tab platform is designed to help these medicines survive digestion and pass into the bloodstream. Entera is based in Jerusalem and targets patients and healthcare providers.
- Headquarters
- Jerusalem